Form 4: Alector Director Errol Desouza Reports Significant Equity Grant and Option Awards

Alector, Inc. Director Errol B. Desouza reported the acquisition of 28,700 restricted stock units and 9,450 stock options on June 11, 2025, as part of his compensation.

Summary

• Errol B. Desouza, a Director of Alector, Inc. (ALEC), acquired 28,700 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 11, 2025.
• These RSUs were granted at a price of $0.00 per share and will vest on the earlier of June 11, 2026, or the date of the Issuer's next annual meeting of stockholders.
• Following this transaction, Mr. Desouza beneficially owns 69,950 shares of Common Stock.
• Additionally, Mr. Desouza acquired 9,450 stock options (right to buy) on June 11, 2025, with an exercise price of $1.63 per share.
• These stock options were granted at a price of $0.00 and will vest in 12 equal monthly installments beginning on July 11, 2025, or in full on the earlier of the one-year anniversary of the grant date or the Issuer's next annual meeting of stockholders.
• Following this transaction, Mr. Desouza beneficially owns 9,450 stock options.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The sentiment is positive as the equity grants align the director's interests with shareholders, which is generally viewed favorably. However, it is also a routine compensation event, not indicative of extraordinary news.

Positives

• The grant of restricted stock units and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The transaction was conducted under a Rule 10b5-1(c) plan, indicating a pre-planned and transparent approach to equity compensation.

Future Outlook

The vesting schedules for the restricted stock units and stock options indicate future increases in the director's beneficial ownership of Alector, Inc. equity, contingent on continued service and the achievement of vesting conditions.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice across publicly traded companies, particularly in the biotechnology sector like Alector, Inc., to attract, retain, and incentivize key personnel and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options as a form of director compensation is a common and widely accepted practice in the biotechnology and broader public company landscape, consistent with industry standards for executive and board remuneration.
• The implementation of a Rule 10b5-1(c) plan for these grants is also a standard governance practice, promoting transparency and mitigating concerns about insider trading.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants to the director are intended to align their interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: While not directly impacting all employees, the compensation structure for directors can set a precedent for broader equity incentive programs within the company.

Next Steps

• Vesting of 28,700 restricted stock units on the earlier of June 11, 2026, or the date of the Issuer's next annual meeting of stockholders.
• Vesting of 9,450 stock options in 12 equal monthly installments beginning July 11, 2025, or in full on the earlier of the one-year anniversary of the grant date or the Issuer's next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Alector, ALEC, Form 4, insider transaction, equity compensation, restricted stock units, stock options, director compensation, corporate governance, Rule 10b5-1